Cohortias – FDA approves new lung cancer therapy trial

The Phase I study will assess the preliminary efficacy and safety for LB2102 in SCLC and LCNEC patients.
lung cancer

FDA approves new lung cancer therapy trial

The FDA has approved Legend Biotech’s Investigational New Drug application to proceed with LB2102’s clinical development for treating extensive stage small cell lung cancer (SCLC).

LB2102 is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of extensive SCLC in adult patients.

The open-label, first-in-human Phase I clinical study has been designed for assessing the CAR-T therapy’s safety and preliminary efficacy in extensive stage SCLC patients, as well as in patients with large cell neuroendocrine carcinoma (LCNEC).

It will also determine the recommended dose for the Phase II study.

Legend Biotech Clinical Development vice-president Lida Pacaud said: “Lung cancer is a debilitating disease that often spreads quickly.

lung cancer

“On average, only 7% of patients with SCLC are alive five years after receiving their diagnosis.

“We are eagerly awaiting the start of this Phase I trial, and we hope that the study will provide much needed insight into the potential of this investigational CAR-T therapy.”

The company stated that LB2102 has been designed for targeting delta-like ligand 3 (DLL-3) selectively.

DLL-3 is a ligand which is restricted to various malignancies that include LCNEC, SCLC, certain other neuroendocrine tumors, and some prostate cancers.

Share:

More Posts

Send Us A Message